Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

HPV Vaccine May Benefit HIV-infected Women

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
The findings appear in the journal of acquired immune deficiency syndromes.

Women with HIV may benefit from a vaccine for human papillomavirus (HPV), despite having already been exposed to HPV, a study finds.

Although many may have been exposed to less serious forms of HPV, more than 45 percent of sexually active young women who have acquired HIV appear never to have been exposed to the most common high-risk forms of HPV, according to the study from a National Institutes of Health research network.

HPV is the most common sexually transmitted infection in the world. The virus can infect the anal and genital areas, mouth and throat of males and females. High-risk forms of the virus can cause cancer, including cancer of the cervix.

The researchers noted that earlier studies had found many women with HIV were more likely than were women who did not have HIV to have conditions associated with HPV, such as precancerous conditions of the cervix, as well as for cervical cancer.

"Health care providers may hesitate to recommend HPV vaccines after a girl starts having sex," said study first author Jessica Kahn, M.D., M.P.H. of Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine.

Kahn continued, "However, our results show that for a significant number of young women, HPV vaccine can still offer benefits. This is especially important in light of their HIV status, which can make them even more vulnerable to HPV's effects."

The Centers for Disease Control and Prevention recommends HPV vaccination for girls ages 11-26. If an individual has not been exposed to the virus, approved HPV vaccines can protect against four types of the virus.

Two HPV types, HPV-16 and HPV-18, cause 70 percent of cervical cancers. Two others, HPV-6 and HPV-11, cause 90 percent of genital warts.

At the time the women in the study received their first HPV vaccination, the researchers found that 12 percent had an existing HPV-16 infection and 5 percent had an HPV-18 infection.

Because of their HIV status, these women may be more likely to develop cervical cancer or to develop a cancer that is hard to treat, the researchers said.

"Cervical cancer screening for sexually active young women is an important clinical priority, but our findings suggest it is especially so for women at risk of HIV," said study co-author Bill G. Kapogiannis, M.D., of the Pediatric, Adolescent and Maternal AIDS Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), one of six NIH institutes supporting the study.

Drs. Kahn and Kapogiannis conducted the research in collaboration with colleagues at the NICHD and Albert Einstein College of Medicine, New York City; Jefferson Medical College of Thomas Jefferson University, Philadelphia; New York University School of Medicine; Westat, Inc., Rockville, Md.; and the University of Alabama at Birmingham.

The research was conducted at a network of hospitals affiliated with the NICHD-funded Adolescent Medicine Trials Network for HIV/AIDS Interventions.

Also supporting the study were the National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Cancer Institute and National Center for Research Resources.

The researchers analyzed blood and tissue samples from 99 HIV-positive women between 16 and 23 years old who were given an initial vaccination for HPV.

The researchers examined the samples for evidence of an existing HPV infection as well as previous exposure to the virus.

The researchers tested for the presence of 41 of more than 100 existing types of HPV virus, including 13 high-risk types. They found that 75 percent of the women had an existing HPV infection with at least one type, with 54 percent testing positive for a high-risk type.

However, when examining the two types that cause 70 percent of cervical cancers (HPV-16 and HPV-18), the researchers found that nearly half of the women had no existing infection with either type and showed no evidence of exposure to them.

When the researchers tested for each type of HPV individually, they found that nearly 75 percent of the women had no current HPV-18 infection and no evidence of previous exposure. For HPV-16, 56 percent did not have a current infection or previous exposure.

"Even among women who test positive for one type of HPV, the vaccine may effectively prevent infection with others - especially high-risk forms that cause cancer," Dr. Kahn said. "It’s important that doctors don't withhold the vaccine in these cases, thinking that it's too late for a vaccine to be effective."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
For Most Children with HIV and Low Immune Cell Count, Cells Rebound After Treatment
NIH-funded study finds T-cell level returns to normal with time.
Saturday, March 28, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Autoimmune Disease Super-Regulators Uncovered
Scientists discovered key genetic switches, called super-enhancers, involved in regulating the human immune system.
Tuesday, March 17, 2015
NIH Announces $41.5 Million in Funding for the Human Placenta Project
Better understanding of the placenta promises to improve the health of mothers and children.
Tuesday, March 03, 2015
NIH-funded Scientists Create Potential Long-acting HIV Therapeutic
New molecule also might prevent HIV infection.
Tuesday, February 24, 2015
Link Between Powerful Gene Regulatory Elements and Autoimmune Diseases Revealed
Findings point to potential drug targets.
Thursday, February 19, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Stem Cell Transplants May Halt Progression of Multiple Sclerosis
NIH-funded study yields encouraging early results.
Tuesday, December 30, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
NIH to Admit Patient Exposed to Ebola Virus for Observation
Ebola patients can be safely cared for at any hospital that follows CDC's infection control recommendations.
Wednesday, October 01, 2014
Scientific News
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos